Retirement Systems of Alabama Sells 4,152 Shares of Medpace Holdings, Inc. $MEDP

Retirement Systems of Alabama decreased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.6% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 59,199 shares of the company’s stock after selling 4,152 shares during the period. Retirement Systems of Alabama’s holdings in Medpace were worth $31,351,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Elyxium Wealth LLC acquired a new position in shares of Medpace in the fourth quarter worth approximately $30,000. Allied Private Wealth LLC acquired a new stake in Medpace during the 2nd quarter valued at approximately $31,000. Basecamp Wealth Advisors LLC raised its holdings in Medpace by 187.5% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock worth $33,000 after purchasing an additional 45 shares during the last quarter. Quarry LP bought a new position in Medpace during the 3rd quarter worth approximately $35,000. Finally, Bayban acquired a new position in shares of Medpace in the 4th quarter worth approximately $44,000. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Performance

Medpace stock opened at $581.95 on Friday. The stock has a market capitalization of $16.24 billion, a price-to-earnings ratio of 34.11, a PEG ratio of 2.66 and a beta of 1.15. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The stock’s 50 day moving average price is $533.75 and its two-hundred day moving average price is $491.74.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Insider Activity at Medpace

In other news, Director Cornelius P. Mccarthy III sold 1,140 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total transaction of $690,121.80. Following the transaction, the director owned 12,275 shares in the company, valued at approximately $7,430,916.75. This represents a 8.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO August J. Troendle sold 17,610 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $605.11, for a total transaction of $10,655,987.10. Following the transaction, the chief executive officer directly owned 615,802 shares in the company, valued at $372,627,948.22. This trade represents a 2.78% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 55,371 shares of company stock valued at $30,878,030. 20.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on MEDP. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Truist Financial lifted their target price on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. BMO Capital Markets increased their price target on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Finally, Robert W. Baird lifted their price objective on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.